目的：观察形觉剥夺性豚鼠近视模型中给予中药驻景方或雷珠单抗注射液干预后屈光度、眼轴长度和脉络膜厚度的短期变化。

方法：取出生2wk的豚鼠60只，右眼戴头套诱导形觉剥夺性近视(FDM)动物模型。2wk后随机分为雷珠单抗组、驻景方组和生理盐水组(各组n=20)。雷珠单抗组第1d玻璃体腔注射雷珠单抗注射液0.02mg 1次，驻景方组给予加减驻景方灌胃3.285g/(kg·d)(1.5mL/d)共7d，生理盐水组给予等量生理盐水灌胃。分别测量记录三组豚鼠给药前和给药后1、3d，1wk的屈光度、眼轴长度和脉络膜厚度。

结果：雷珠单抗组给药前后的各值均无差异(P>0.05)。驻景方组和生理盐水组给药后1、3d的屈光度明显降低、眼轴长度缩短、脉络膜厚度增厚(P<0.05)，且3d时两组的各值变化最明显，但均在1wk时恢复到给药前的水平。三组间给药1、3d时生理盐水组和驻景方组的屈光度均低于雷珠单抗组，且眼轴长度较短，脉络膜厚度较厚(P<0.05)，给药3d时生理盐水组的各值变化最明显(P<0.05)。给药1wk时三组间各指标均无差异(P>0.05)。

结论：形觉剥夺性近视恢复期有一个短暂的脉络膜增厚时期，雷珠单抗注射液全程明显抑制了形觉剥夺性近视恢复期脉络膜的增厚，驻景方在3d时开始出现轻微的增厚抑制，均只持续了短暂的1wk时间。

METHODS: A Guinea pigs model of form-deprived(FD)myopia were randomly divided into 3 groups: Zhujing formula group, ranibizumab group and saline group(n=20 for each group). Zhujing formula group were fed daily with Zhujing formula solution 3.285g/(kg·d)(1.5mL/d)for 1wk. Ranibizumab group were treated with(intravitreal injections of 0.02mg)ranibizumab at the first day. Saline group were fed with 1.5mL 0.9% saline at the first day. The refraction(Diopter), axial length and choroidal thickness were measured before and at day 1, 3 and 7d postoperative.

RESULTS: The spherical equivalent(SE), axial length and choroidal thickness in ranibizumab group showed no significant trend after intravitreal injection(P>0.05). However, SE and axial length showed trendency to greater myopic shift in the Zhujing formula group and the saline group(P<0.05). The effect began to appear on the first day after administration, achieved the maximum effect after 3d, and faded completely until 7d. On the first day after administration, the diopter and the axial length in ranibizumab group showed the lowest among three groups(P<0.05), and choroid thickness showed the thickest among three groups(P<0.05). At 3d after administration, the diopter and the axial length in the saline group showed the lowest among three groups, and choroid thickness showed the thickest among three groups(P<0.05). There was no significant difference in the parameters among the three groups at 1wk after administration(P>0.05).

CONCLUSION: There is a temperary choroidal thickening of the form deprivation myopia recovery period. The ranibizumab inhibited the thickening of the choroid in the whole recovery period of form deprivation myopia, Zhujing formula slight inhibited the thickening at 3d, and the all change persisted only for 1wk.